Searchable abstracts of presentations at key conferences in endocrinology

ea0004s15 | Transcriptional control of endocrine development and function | SFE2002

Genetic Control of Sex Differentiation

Hughes I , Martin H , Jaaskelainen J

Sex differentiation is the development of the internal and external genitalia following gonad determination. Genital ridge formation is regulated by WT1, SF1 and LHX9 whereas SRY is a major player in testis determination. Quite how SRY functions as a transcription factor is still unknown twelve years after the (i)SRY(/i) gene was cloned. How testis determination is regulated is incomplete, as the cause of sex reversal is unknown in the majority of patients with XY gonadal dysg...

ea0029p1810 | Thyroid cancer | ICEECE2012

Utility of the perciutaneous ethanol injection (PEI) in the treatment of metastatic adenopathies of thyroid carcinoma

Santamaria J. , Ruiz de azua T. , Batanero R. , Elias E. , Martin I. , Peteiro D.

Introduction: Surgery is the usual therapeutic approach for treatment of recurrent lymph node metastases due to thyroid carcinoma. However, there is no evidence of improvement in the final prognosis and is not an option without risk, especially in patients such as those who already underwent several surgeries or suffered from comorbidities.PEI is a useful alternative for treatment of selected thyroid diseases. Here, we present our experience in patients ...

ea0049gp241 | Thyroid Cancer & Thyroid Case Reports | ECE2017

Thyroid-related adverse events in patients treated with Nivolumab

Peiro I , Martin L San , Simo-Servat A , Otero J , Ruffinelli JC , Nadal E , Iglesias P , Diez JJ , Villabona C

Introduction: Nivolumab is an antibody that binds to and blocks the activation of programmed-death-receptor 1(PD-1), promoting the activation of T-cells against tumor cells. Thyroid dysfunction (TD) is one of the most common immuno-related adverse events, with incidence up to 10% in patients treated with PD-1/PD-L1 blockade.Objective: To report our experience of Nivolumab-TD in patients with advanced cancer.Methods: All patients di...